VIR-2482 is an investigational intramuscularly administered influenza A-neutralising mAb. It has been shown in vitro to cover all major influenza A strains that have arisen since the 1918 ...

Being developed as a potential treatment for both pandemic avian and seasonal influenza A infections, CC-42344 claims to have demonstrated 'excellent' in vitro antiviral activity against a range ...

RNAi-based sequence-specific therapeutic agents can maintain pace with the high rate of mutation of influenza virus and HIV, there is a great potential for such therapeutic agents in the near future.

The HA of avian influenza viruses binds to "avian-type ... It was an experimental in vitro test that, via a range of different laboratory techniques, introduced mutations at a specific point ...

The global in vitro diagnostics market size was reached at USD 83.41 billion in 2024 and is expected to expand around USD 129.14 billion by 2033, with a CAGR of 4.97% from 2024 to 2033. The market is ...

In the near future, gene silencing against influenza viruses may also be successfully applied in antiviral therapeutics. There are several bottlenecks in the successful application of gene ...